Barclays raised the firm’s price target on Guardant Health (GH) to $120 from $85 and keeps an Overweight rating on the shares. The firm adjusted ratings and price targets in the life sciences and diagnostics tools space as part of its 2026 outlook. The last of the estimate cuts, recovering end markets and tools being the “most under-owned space in healthcare” creates a “great setup” for outperformance of the tools group in 2026, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- GeneDx price target raised to $200, named 2026 Top Pick at BTIG
- Guardant Health price target raised to $140, named 2026 Top Pick at BTIG
- Guardant Health price target raised to $135 from $100 at Citi
- Guardant Health assumed with an Overweight at Morgan Stanley
- Private Markets: Prediction market platform Kalshi secures $300M